Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;23(2):193-195.
doi: 10.1016/S1470-2045(21)00715-4. Epub 2021 Dec 23.

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Hagai Ligumsky  1 , Herut Dor  2 , Tal Etan  3 , Inbal Golomb  3 , Alla Nikolaevski-Berlin  4 , Inbal Greenberg  2 , Tamar Halperin  5 , Yoel Angel  6 , Oryan Henig  7 , Avishay Spitzer  8 , Marina Slobodkin  9 , Ido Wolf  3 ; COVI3 study investigators
Affiliations

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Hagai Ligumsky et al. Lancet Oncol. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

YA declares receiving research grants from Pfizer, outside the scope of this work. AS is partially supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center, and by a research grant from the Estate of Tully and Michele Plesser. IW reports speaker fees and fees for consultancy from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Beyond Air, AstraZeneca, and Novartis; contracts or research funding from Roche, Novatis, Beyond Air, and Merck Sharp & Dohme; participation on a data safety monitoring board or advisory board of Merck Sharp & Dohme and AstraZeneca; participation in committee of Israeli Cancer Association; and stock options in Breath of life. All other authors declare no competing interests. COVI3 study investigators are listed at the appendix (p 4).

Figures

Figure
Figure
SARS-CoV-2 S IgG antibody values in serum samples of actively treated patients with cancer (n=72) and healthy controls (n=144) before (blue circles dots) and after (red squares) the third dose of BNT162b2 vaccine Boxes represent median SARS-Cov-2 S IgG antibody concentrations and whiskers represent upper and lower quartiles. Each dot represents one participant. The y-axis (log10 scale) represents SARS-Cov-2 S IgG antibody WHO BAU/ML values transformed to log10 scale. Dashed line represents cutoff level for seropositivity. Significant differences were assessed by related-samples sign test for the comparison within a group and independent-samples Mann-Whitney U and Kolmogorov-Smirnov tests. After a third dose patients with cancer have lower plasma concentrations of SARS-Cov-2 S IgG antibodies compared with healthy individuals (p=0·00011).
See this image and copyright information in PMC

References

    1. Waldhorn I, Holland R, Goshen-Lago T, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 2021;11:2430–2435. - PubMed
    1. Eliakim-Raz N, Massarweh A, Stemmer A, Stemmer SM. Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment. JAMA Oncol. 2021;7:1716–1718. - PMC - PubMed
    1. Ligumsky H, Safadi E, Etan T, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst. 2021 doi: 10.1093/jnci/djab174. published online Aug 28. - DOI - PMC - PubMed
    1. Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581–583. - PMC - PubMed
    1. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385:e85. - PMC - PubMed

Publication types